

澳大利亚生物技术协会 澳大利亚医疗技术公司名录



公司资料

公司名称: Agincourt Bio Consulting

关键联系人姓名: Pete Ratcliffe

关键联系人职位: 董事总经理/首席执行官

公司网址: www.agincourtbioconsulting.com

公司地址: 110 Rob Riley Circuit, Bonner, 2914, Canberra, ACT

该公司尚未上市。

关于公司

Agincourt Bio Consulting 是一家跨国咨询顾问公司, 专门针对物色合作伙伴、实现商业化策略和寻找投资者提供独一无二的定制解决方案。

我们在医疗、制药、生命科学和医疗器械等行业拥有 20 年以上的商业经验, 致力于推进跨境许可、共同研发、合资企业参与和交易等事宜。

Agincourt 同样注重投资知识产权并进行知识产权许可和商业化, 并且拥有自己的技术、平台、器械、诊断和临床项目投资组合渠道。

关键或领先技术

REVAC (快速增强型病毒扩大培养) 诊断试剂盒是一种快速病毒检测方法, 能检测试样中病毒的生长情况及所属类别。该试剂盒能检测所有活病毒, 在墨尔本皇家儿童医院的使用历史已逾 10 年且未出现任何误报情况; 不仅能在 6-40 小时内即提供临床相关结果, 与分子检测方法配合使用时还可突破任一单个检测方法存在的局限性。

墨尔本皇家儿童医院对该试剂盒的实验室使用结果如下:

1. 在 6-40 小时内迅速检测出活性病毒;
2. 检测高特异性和高灵敏度试样中的活性病毒;
3. 迅速检测混合感染;

4. 检测可重现、操作简单且结果分析较容易。因此，与其他检测系统相比，此方法所要求的技术人员初期培训较少，并且能极大地提升每位化验员的工作效率；
5. 每次检测费用大大低于使用新技术的病毒检测系统，也同样低于当前被视为“黄金标准”的病毒培养检测系统。
6. 该检测系统能进行病毒分离培养，能够对新病毒生物体进行归类并测定原分离病毒的活性或毒性。
7. REVAC 方法能及时提供最终结果，可保证有效进行抗病毒治疗（如果未能在感染后 72 小时内进行抗病毒治疗，那么疗效将大打折扣）。

类别

诊断学：诊断病毒学

关键或领先技术的发展阶段

已注册（已完成 FDA 审查）
产品即将实现商业化

所寻机遇

REVAC 技术和快速诊断试剂盒即将实现商业化，能立即产生销售收入为企业盈利，并可在亚洲、美国和欧洲许可使用。该公司正在寻找合作伙伴，就该试剂盒在中国的商业化、上市、市场营销、分销和销售事宜展开合作，并会提供标准预付金、商业化里程碑服务和销售提成。

Directory of Australian medtech companies



COMPANY DETAILS

Company name: Agincourt Bio Consulting

Key contact name: Pete Ratcliffe

Job title of key contact: Managing Director / CEO

Company website address: www.agincourtbioconsulting.com

Company address: 110 Rob Riley Circuit, Bonner, 2914, Canberra, ACT

The company is Unlisted.

ABOUT THE COMPANY

Agincourt Bio Consulting is a global advisory and consultancy firm, specialising in providing uniquely tailored approaches to partner identification, commercialization strategies and targeted exposure to Investors.

With over 20 years commercial experience in the healthcare, pharmaceutical, life science and medical device sectors we focus on facilitating cross border licensing, co-development, joint venture engagements and transactions.

Agincourt also invests in, licenses and commercialises IP and has its own portfolio pipeline of technologies, platforms, devices, diagnostics and clinical programs.

KEY OR LEAD TECHNOLOGY

The REVAC diagnostic test kit (Rapid Enhanced Viral Amplification Culture) is a rapid viral detection test involving growth of virus from specimens and the detection and categorisation of the growing virus. The test can detect ANY live virus, has been used in the Royal Melbourne Children's Hospital for 10 years with No false positive results, provides clinically relevant results between 6-40hrs and when combined with molecular detection methods overcomes the limitations of any single test approach.

Laboratory use of the tests at the Royal Children's Hospital in Melbourne has found the following:

1. Rapid detection of viable virus within 6 - 40 hours
2. Detection of viable virus from specimens with very high specificity and sensitivity
3. Rapid detection of mixed infections;
4. Test is reproducible, simple to operate and easy to interpret. As a result, less preliminary training of technicians is required compared to other systems and throughput per individual laboratory technician can be increased markedly;
5. Cost per test is significantly less than costs for newer technology viral detection systems and is less than current "gold standard" virology culture detection systems.
6. The testing system provides viral culture isolates which can enable typing of new viral organisms and determination of viability or virulence of the original virus isolated.
7. The REVAC method provides definitive results in a time frame that enables effective use of antiviral treatment (If antiviral treatment is not commenced within 72 hours of onset of infection, its effectiveness is greatly reduced).

Category

Diagnostics: Diagnostics virology

Point of development of key or lead technology

Has achieved registration (FDA Review Completed)
Product ready to be commercialized

OPPORTUNITIES SOUGHT

The REVAC technology and rapid diagnostic kit is ready to commercialize, will provide immediate sales revenues delivered directly to the bottom line and is available to license across Asia, the USA and Europe. The company seeks a partner to commercialize, launch, market, distribute and sell the test kit in China with standard upfront, commercialization milestone and sales royalties.